Once diabetes drugs, SGLT2 inhibitors are now key therapies for heart failure—even in patients without diabetes. A new primary-care guide reviews indications, benefits, and practical prescribing tips to help clinicians integrate these agents into routine HF care.

Are PCPs ready to adopt SGLT2 inhibitors beyond diabetes?

While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.